Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Muchtar E, et al. Among authors: sanchorawala v. JAMA Oncol. 2024 Oct 1;10(10):1362-1369. doi: 10.1001/jamaoncol.2024.2629. JAMA Oncol. 2024. PMID: 39088206
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Gertz MA, et al. Among authors: sanchorawala v. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381. Am J Hematol. 2005. PMID: 16044444 Free article. Review.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Reece DE, et al. Among authors: sanchorawala v. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. Blood. 2009. PMID: 19498019 Free article. Clinical Trial.
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Reece DE, et al. Among authors: sanchorawala v. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11. Blood. 2011. PMID: 21562045 Free article. Clinical Trial.
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Cibeira MT, et al. Among authors: sanchorawala v. Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9. Blood. 2011. PMID: 21828140 Free PMC article.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Comenzo RL, et al. Among authors: sanchorawala v. Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. Leukemia. 2012. PMID: 22475872 Review.
Update on treatment of light chain amyloidosis.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Mahmood S, et al. Among authors: sanchorawala v. Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619. Haematologica. 2014. PMID: 24497558 Free PMC article. Review.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Reece DE, et al. Among authors: sanchorawala v. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. Blood. 2014. PMID: 25202139 Free PMC article. Clinical Trial.
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Merlini G, et al. Among authors: sanchorawala v. Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Leukemia. 2016. PMID: 27416985 Free PMC article. Review.
232 results